CRVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CervoMed Inc (CRVO) is not a strong buy for a beginner, long-term investor at this time. While there are potential catalysts in the pipeline, such as the Phase 3 study for dementia with Lewy bodies, the company's financials are weak, and the technical indicators do not suggest a strong entry point. Additionally, there are no significant trading signals or recent influential trades to support a buy decision.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 43.557, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 4.467, with key support at 4.001 and resistance at 4.933. Overall, the technical indicators suggest a bearish trend.
The company's neflamapimod program is advancing with strong Phase 2 results and alignment with the FDA for a Phase 3 study in dementia with Lewy bodies. Analysts maintain a Buy rating despite mixed price target adjustments.
The company reported a significant net loss of $27 million for FY25 and a 58.9% YoY revenue decline. Cash reserves are expected to last only six months, indicating potential capital-raising needs under less favorable terms. Additionally, there are no significant hedge fund or insider trading trends.
In Q4 2025, revenue dropped by 99.60% YoY to $8,726, while net income improved by 20.60% YoY to -$8,087,290. EPS increased by 12.99% YoY to -0.87. Gross margin remained stable at 100%. The financials highlight weak revenue performance but slight improvements in net income and EPS.
Chardan raised the price target to $21 from $15, citing confidence in the Phase 3 study. Roth Capital lowered the price target to $11 from $19, reflecting concerns about capital-raising needs. Both analysts maintain a Buy rating, but the mixed price target changes indicate uncertainty.
